Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12482169 | 0.93 | PKM (0.39) | PKMSMN1; SMN2TSHRNPC1RAB9A | |
| SCHEMBL15341140 | 0.90 | TSHR (0.42) | PKMSMN1; SMN2TSHRNPC1RAB9A | |
| SCHEMBL15333651 | 0.89 | PKM (0.39) | PKMSMN1; SMN2TSHRNPC1RAB9A | |
| SCHEMBL12481840 | 0.87 | PKM (0.39) | PKMSMN1; SMN2TSHRNPC1RAB9A | |
| SCHEMBL12481888 | 0.86 | PKM (0.39) | PKMSMN1; SMN2TSHRNPC1RAB9A | |
| SCHEMBL15344244 | 0.85 | — | — | |
| SCHEMBL12481977 | 0.84 | ATP4A (0.39) | PKMSMN1; SMN2TSHRNPC1RAB9A | |
| SCHEMBL12482158 | 0.83 | PKM (0.40) | PKMSMN1; SMN2TSHRNPC1RAB9A | |
| SCHEMBL12481871 | 0.83 | PKM (0.41) | PKMSMN1; SMN2TSHRNPC1RAB9A | |
| SCHEMBL12481967 | 0.82 | PKM (0.41) | PKMSMN1; SMN2TSHRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029295-B2 | Pyridazinone compound and herbicide and noxious arthropod controlling agent comprising it | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-05-12 | — | — | US | disclosed |
| EP-2658845-B1 | PYRIDAZINONE COMPOUND AND HERBICIDE AND NOXIOUS ARTHROPOD CONTROLLING AGENT COMPRISING IT | SUMITOMO CHEMICAL CO (JP) | 2015-02-25 | — | — | EP | disclosed |
| EP-2658845-A1 | PYRIDAZINONE COMPOUND AND HERBICIDE AND NOXIOUS ARTHROPOD CONTROLLING AGENT COMPRISING IT | Sumitomo Chemical Company Limited (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-20130281299-A1 | PYRIDAZINONE COMPOUND AND HERBICIDE AND NOXIOUS ARTHROPOD CONTROLLING AGENT COMPRISING IT | SUMITOMO CHEMICAL COMPANY,LIMITED (JP) | 2013-10-24 | — | — | US | disclosed |
| WO-2012091156-A1 | PYRIDAZINONE COMPOUND AND HERBICIDE AND NOXIOUS ARTHROPOD CONTROLLING AGENT COMPRISING IT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281299-A1 | PYRIDAZINONE COMPOUND AND HERBICIDE AND NOXIOUS ARTHROPOD CONTROLLING AGENT COMPRISING IT | ACHE, CBR3, DDT | PKM 311/4885SMN1; SMN2 2614/4885TSHR 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.